These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31566408)

  • 61. Hepatocellular carcinoma: The beginning of a long journey.
    Cascinu S
    Dig Liver Dis; 2009 Oct; 41(10):707-8. PubMed ID: 19699696
    [No Abstract]   [Full Text] [Related]  

  • 62. Reply to M. Bouattour et al.
    Cainap C; McKee MD; Ricker JL
    J Clin Oncol; 2015 Aug; 33(22):2486. PubMed ID: 26033815
    [No Abstract]   [Full Text] [Related]  

  • 63. Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma.
    Nagahama H; Okada S; Okusaka T; Ishii H; Ikeda M; Nakasuka H; Yoshimori M
    Jpn J Clin Oncol; 1997 Oct; 27(5):321-4. PubMed ID: 9390209
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
    Faivre S; de Gramont A; Raymond E
    Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
    [No Abstract]   [Full Text] [Related]  

  • 65. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma.
    Gao J; Inagaki Y; Song P; Qu X; Kokudo N; Tang W
    Pharmacol Res; 2012 Jan; 65(1):23-30. PubMed ID: 22138044
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Molecularly targeted therapy in hepatocellular carcinoma.
    Huynh H
    Biochem Pharmacol; 2010 Sep; 80(5):550-60. PubMed ID: 20371362
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Regression of a hepatocellular carcinoma following treatment with octreotide and tamoxifen in a patient with advanced alcoholic cirrhosis.
    Senturk H; Canbakan B; Cumali R
    J Gastroenterol Hepatol; 2004 Jun; 19(6):719-20. PubMed ID: 15151636
    [No Abstract]   [Full Text] [Related]  

  • 68. [The chemotherapy for hepatocellular carcinoma].
    Nagano H; Sakon M; Monden M
    Gan To Kagaku Ryoho; 2003 Nov; 30(12):1895-900. PubMed ID: 14650956
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?
    Chen WC; Chen W; Tseng GC; Lai HC; Shih CM; Hsia TC
    Liver Int; 2010 Nov; 30(10):1548-9. PubMed ID: 20345702
    [No Abstract]   [Full Text] [Related]  

  • 72. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
    Oikonomopoulos G; Aravind P; Sarker D
    Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.
    Brunetti O; Gnoni A; Licchetta A; Longo V; Calabrese A; Argentiero A; Delcuratolo S; Solimando AG; Casadei-Gardini A; Silvestris N
    Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31640191
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
    Boige V; Barbare JC; Rosmorduc O;
    Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
    [No Abstract]   [Full Text] [Related]  

  • 75. Sorafenib for the treatment of advanced hepatocellular carcinoma.
    Connock M; Round J; Bayliss S; Tubeuf S; Greenheld W; Moore D
    Health Technol Assess; 2010 May; 14 Suppl 1():17-21. PubMed ID: 20507799
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Oral chemotherapy for the treatment of hepatocellular carcinoma.
    Yamamoto S; Kondo S
    Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
    [TBL] [Abstract][Full Text] [Related]  

  • 77. mTor as a potential target for the prevention and treatment of hepatocellular carcinoma.
    Buitrago-Molina LE; Vogel A
    Curr Cancer Drug Targets; 2012 Nov; 12(9):1045-61. PubMed ID: 22873368
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.
    Gao JJ; Shi ZY; Xia JF; Inagaki Y; Tang W
    World J Gastroenterol; 2015 Nov; 21(42):12059-70. PubMed ID: 26576091
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Interplay of drug metabolizing enzymes with cellular transporters.
    Böhmdorfer M; Maier-Salamon A; Riha J; Brenner S; Höferl M; Jäger W
    Wien Med Wochenschr; 2014 Nov; 164(21-22):461-71. PubMed ID: 25271108
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Time for a new Canada Health Act.
    CMAJ; 2000 Sep; 163(6):689, 691. PubMed ID: 11022578
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.